Dermata therapeutics announces closing of $2.55 million private placement priced at-the-market under nasdaq rules

San diego, ca / access newswire / january 23, 2025 / dermata therapeutics, inc. (nasdaq:drma)(nasdaq:drmaw) ("dermata," or the "company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 2,007,880 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 2,007,880 shares of common stock at a purchase price of $1.27 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrant priced at-the-market under the rules of the nasdaq stock market. the gross proceeds from the offering were approximately $2.55 million, prior to deducting placement agent's fees and other offering expenses payable by the company.
NDAQ Ratings Summary
NDAQ Quant Ranking